The Oregon Alzheimer's Disease Center Biomarkers and Genetics Core was established in order to promote research utilizing genetic, plasma, and cerebrospinal fluid biomarkers of Alzheimer's disease and relevant mechanisms.
The Specific Aims are: 1) To obtain and make available for research, biomarker specimens (DNA. plasma, and CSF) from OADC subjects, including healthy control subjects, subjects with mild cognitive impairment (MCI), and subjects with AD and other demenfias. 2) To obtain and make available for research, biomarker data on OADC subjects. This will include: a) apolipoprotein E (APOE) genotype on all subjects, b) single nucleotide polymorphism (SNP) profiles on select aging cohorts, and c) CSF Ap42, tau, BDNF, and F2-isoprostanes on select cohorts, d) plasma biomarker data on select cohorts. 3) To foster collaborative research involving genetics and other biomarkers emphasizing the research focus of the OADC. Research themes supported by the Core include 1) Identification of genetic predictors of both healthy brain aging and neurodegenerative dementia;2) Identification and validation of CSF and plasma biomarkers of neurodegeneration and mechanisms of neurodegeneration suitable for identification of high risk subjects, for identification of target mechanisms, and for use as outcome measures in clinical trials;3) Identification of CSF and plasma biomarkers of environmental predictors of both healthy brain aging and neurodegenerafive dementia. The Core maintains specimen banks and provides samples to qualified investigators with appropriate IRB approvals. Clinical and other data is also made available to invesfigators within HIPAA guidelines and according to local IRB regulations.
The increasing emphasis on early intervention to prevent Alzheimer's disease in asymptomatic subjects will require that subjects and outcomes be characterized by a variety of biomarkers rather than relying on clinical outcomes alone. The understanding and utilization of these markers of risk and surrogate markers of disease will depend on the availability of the types of samples and data to be generated by this Core.
|Kim, Julia; Schweizer, Tom A; Fischer, Corinne E et al. (2017) The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. J Alzheimers Dis 55:381-389|
|Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968|
|Mattos, Meghan K; Snitz, Beth E; Lingler, Jennifer H et al. (2017) Older Rural- and Urban-Dwelling Appalachian Adults With Mild Cognitive Impairment. J Rural Health 33:208-216|
|Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214|
|Wardzala, Casia; Murchison, Charles; Loftis, Jennifer M et al. (2017) Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology (Berl) :|
|Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738|
|Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384|
|Jutkowitz, Eric; MacLehose, Richard F; Gaugler, Joseph E et al. (2017) Risk Factors Associated With Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia Patients. J Gerontol A Biol Sci Med Sci 72:251-258|
|Boise, Linda; Hinton, Ladson; Rosen, Howard J et al. (2017) Willingness to Be a Brain Donor: A Survey of Research Volunteers From 4 Racial/Ethnic Groups. Alzheimer Dis Assoc Disord 31:135-140|
|Dodge, Hiroko H; Zhu, Jian; Woltjer, Randy et al. (2017) Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. Alzheimers Dement 13:613-623|
Showing the most recent 10 out of 421 publications